A Unique Opportunity in Biotech

---

Synkrino Development Company is venturing into a white space of significant opportunity. 

There  are an abundance of companies, funds and incubators that invest in  early- and late-stage biotech. The vast majority engage with select  companies via equity investment or outright acquisitions. Few investors  do so via asset specific investments, and there is a clear preference  for later stage assets. 

We  partner with biotech - both privately owned and academia based - on  early-stage assets, across technology platforms, biological targets,  TAs, and diseases.

The novel capital structure of SDC is a mix of equity and debt offering attractive returns to both shareholders and providers of credit facilities balancing volatility and investment yield - a unique structure that provides uncommon flexibility and agility in asset and portfolio management.

Our capital is always deployed based on rigorous diligence of the potential of science and assets, not on the IP originating companies.